Executive Summary Antibody drug conjugates (ADCs) have become one of the most important innovations in oncology and the broader biotech industry in recent years. Over the past decade, antibody drug conjugates have evolved from early-stage research tools into an integrated system spanning science, clinical development, manufacturing, and market strategy. Understanding ADCs solely from the perspective of molecular design or clinical efficacy is no longer sufficient. Antibody d

Executive Summary- ADC clinical development Antibody–drug conjugates (ADCs) have achieved major advances at the scientific and engineering levels, yet clinical success remains highly variable. Many ADCs: show strong performance in preclinical models demonstrate early responses in Phase I trials ultimately fail in Phase II or Phase III studies This indicates that the challenge is not solely molecular design, but rather: ADC clinical development strategy Successful ADC programs